Newcardio, Inc. (NWCI)

[califax]

FOX Business NEWS



http://www.foxbusiness.com/story/markets/industries/health-care/buyout-works-nwci-awarded-key-patent/

Friday, January 15, 2010
"Buyout in the Works" After NWCI is Awarded Key Patent


Jan 15, 2010 (BAYSTREET NEWSWIRE via COMTEX) ----The same biotech news portal that reported RXI Pharmaceuticals' (Nasdaq:RXII) now confirmed partnership talks weeks ahead of time is now reporting that another buyout in the sector may be in the works at this moment.

Their report comes on the heels of Thursday morning's key patent news announcement for small cap innovator, NewCardio (NWCI.OB).

According to BioMedReports, the Silicon Valley based company with a very small share float became the subject of some "credible buyout rumors" on the last day of the recent healthcare conferences in San Francisco.

"Rumors began to fly that the company was suddenly in deep negotiations regarding a buy out," reports M.E. Garza. "After chasing the story, and seeing a key patent announcement hit the news wires on Thursday morning, its my opinion that if the buyout occurs, it will could send shares of NewCardio somewhere between $10 and $14." According to Garza, the company has a hot new technology that is shaping up to be not only the next great diagnostics tool in cardiovascular medicine, but could also turn into "the ultimate medical phone app." There is talk about a hardware/software combo that would allow anyone to hold a smart phone-like device up to their chest in order to interpret/communicate the readings directly to a doctor.

Designers of this technology (who come from a tech background designing chips and microprocessors) have figured out that a great number of doctors simply do not know how to interpret heart monitor signals either correctly or accurately. They feel that EKG technology is "under utilized" as a diagnostics tool and see a multi-billion dollar market for their products.

According to an upbeat presentation at the OneMedForum in San Francisco this week, NewCardio is said to be entering the commercial phase as a cardiac diagnostic and services company.

The company's proprietary software platform technologies reportedly provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's three-dimensional ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. Developing...

Copyright 2010 BAYSTREET NEWSWIRE